Arvinas to Host Webcast Presentation of New Clinical Data from ARV-471 and ARV-110 PROTAC® Protein Degrader Development Programs
11 déc. 2020 16h15 HE
|
Arvinas Inc.
– Event to be webcast live on Monday, December 14, 2020 at 8:00 a.m. ET – NEW HAVEN, Conn., Dec. 11, 2020 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology...
Arvinas to Participate in Upcoming Virtual Investor Conferences
25 nov. 2020 07h00 HE
|
Arvinas Inc.
NEW HAVEN, Conn., Nov. 25, 2020 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today...
Arvinas Reports Third Quarter 2020 Financial Results and Provides Corporate Update
05 nov. 2020 07h00 HE
|
Arvinas Inc.
– First patient dosed in Phase 2 dose expansion cohort of ARV-110 trial – – Dose escalation for Phase 1/2 clinical trials of ARV-110 and ARV-471 continues; program updates planned for December 2020 –...
Arvinas Announces Pipeline Programs Targeting Validated and Classically “Undruggable” Disease-Causing Proteins
14 oct. 2020 07h00 HE
|
Arvinas Inc.
NEW HAVEN, Conn., Oct. 14, 2020 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today...
Arvinas to Present at the 3rd Annual Targeted Protein Degradation Summit
06 oct. 2020 17h17 HE
|
Arvinas Inc.
NEW HAVEN, Conn., Oct. 06, 2020 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today...
Arvinas to Present at the Citi 15th Annual BioPharma Virtual Conference
04 sept. 2020 07h00 HE
|
Arvinas Inc.
NEW HAVEN, Conn., Sept. 04, 2020 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today...
Arvinas to Present at the 2020 Wedbush PacGrow Virtual Healthcare Conference
07 août 2020 07h00 HE
|
Arvinas Inc.
NEW HAVEN, Conn., Aug. 07, 2020 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today...
Arvinas Reports Second Quarter 2020 Financial Results and Provides Corporate Update
04 août 2020 07h00 HE
|
Arvinas Inc.
NEW HAVEN, Conn., Aug. 04, 2020 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biopharmaceutical company creating a new class of drugs based on targeted protein degradation,...
Arvinas Appoints Wendy Dixon, Ph.D., to its Board of Directors
29 juin 2020 16h30 HE
|
Arvinas Inc.
NEW HAVEN, Conn., June 29, 2020 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today...
Arvinas to Present Virtually at the BMO 2020 Prescriptions for Success Healthcare Conference
17 juin 2020 07h00 HE
|
Arvinas Inc.
NEW HAVEN, Conn., June 17, 2020 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today...